Researchers Use New Techniques To Assess PTSD

Veterans of () and (OIF) frequently experience high rates of PTSD along with and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield is to search for biomarkers — indicators of a biological state that can be easily and reliably measured in people with an illness — to see if their presence or absence can predict symptoms that an individual will experience and identify strategies.

Dr. and her team at and the sought to determine if there are biomarkers associated with . They hypothesized that veterans who have PTSD (and who often experience depression and pain symptoms) show changes in neurosteroids, which are thought to play a key role in responsiveness to stress.

Dr. Marx based her approach on prior work involving showing that levels of neurosteroids found in blood samples accurately reflect levels found in the brain. Dr. Marx measured blood neurosteroid levels in 90 male /OIF veterans to examine whether they may be predictive of PTSD, depression, and pain symptoms. She found that several candidate biomarkers could be important to identifying the changes that occur in the brain with PTSD, which could aid in the development of more effective treatments.

“The neurosteroid looks like a particularly promising biomarker that we might use to help assess in PTSD, depression, and pain disorders, understand their underpinnings, develop new treatment options, and predict ,” said Marx, an Associate Member of .

Her work was funded by the Veterans Administration, , the Department of Defense, and .

, founded in 1961, is a professional organization of more than 700 leading scientists, including four Nobel Laureates. ’s mission is to further research and education in neuropsychopharmacology and related fields.

Source: American College of Neuropsychopharmacology

  • Share/Bookmark